BIO-SPAN: BIOsimilar switch, Study on Persistence and role of Attribution and Nocebo

Trial Profile

BIO-SPAN: BIOsimilar switch, Study on Persistence and role of Attribution and Nocebo

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatic disorders; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BIO-SPAN
  • Most Recent Events

    • 02 Apr 2018 According to results (6-Month) published in the Arthritis and Rheumatology Journal, the last six months evaluation was performed in May 2017.
    • 02 Apr 2018 According to results (6-Month) published in the Arthritis and Rheumatology Journal, secondary endpoints for this study also included reasons for SB4 or ENB discontinuation, prediction of SB4 discontinuation and differences in disease activity measures over six months.
    • 02 Apr 2018 Results (6-Month) published in the Arthritis and Rheumatology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top